230 related articles for article (PubMed ID: 37051586)
1. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
Singh G; Tolkachjov SN; Farberg AS
Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
4. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
[TBL] [Abstract][Full Text] [Related]
5. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
[TBL] [Abstract][Full Text] [Related]
6. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
7. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
8. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
9. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Specification of Benefit of Adjuvant Radiation Therapy.
Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38810706
[TBL] [Abstract][Full Text] [Related]
10. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
11. Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs.
Somani AK; Ibrahim SF; Tassavor M; Yoo J; Farberg AS
J Clin Aesthet Dermatol; 2024 Jan; 17(1):41-44. PubMed ID: 38298751
[TBL] [Abstract][Full Text] [Related]
12. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
13. Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance.
Moody BR; Farberg AS; Somani AK; Taylor WA
Dermatol Ther (Heidelb); 2024 Apr; 14(4):861-873. PubMed ID: 38521873
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
15. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: Analysis of recurrence-free survival.
Samsanavičius D; Kaikaris V; Norvydas SJ; Liubauskas R; Valiukevičienė S; Makštienė J; Maslauskas K; Rimdeika R
Medicina (Kaunas); 2016; 52(5):276-282. PubMed ID: 27746117
[TBL] [Abstract][Full Text] [Related]
17. Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management.
Arron ST; Blalock TW; Guenther JM; Hyams DM; Ibrahim SF; Koyfman SA; Wysong A
J Drugs Dermatol; 2021 Jun; 20(6):5s-s11. PubMed ID: 34076385
[TBL] [Abstract][Full Text] [Related]
18. Using Gene Expression Profiling to Personalize Skin Cancer Management.
LeQuang JA
J Clin Aesthet Dermatol; 2022 Nov; 15(11 Suppl 1):S3-S15. PubMed ID: 36405422
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
Stratigos A; Garbe C; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Becker JC; Zalaudek I; Saiag P; Middleton MR; Bastholt L; Testori A; Grob JJ; ; ;
Eur J Cancer; 2015 Sep; 51(14):1989-2007. PubMed ID: 26219687
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Que SKT; Zwald FO; Schmults CD
J Am Acad Dermatol; 2018 Feb; 78(2):249-261. PubMed ID: 29332705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
